Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia

Seminars in Hematology
Stephen G O'Brien, Michael W N Deininger

Abstract

The International Randomized Study of Interferon and STI571 (IRIS) study prospectively compared imatinib with interferon-alpha/low-dose cytarabine (IFN/LDAC) in 1,106 newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML). Patients not responding to or intolerant of their assigned treatment were allowed to cross over. At 18 months, the projected probability of achieving a complete cytogenetic response was 76.2% for imatinib and 14.5% for IFN/LDAC, respectively (P <.01). Freedom from progression to accelerated phase or blast crisis was 96.7% for imatinib versus 91.5% for IFN/LDAC (P <.01). At the time of the analysis, 85.7% of imatinib-treated patients continued on first-line therapy, but only 10.8% of patients continued with IFN/LDAC. Most cross-overs to imatinib were due to interferon-intolerance. Overall survival was not different in the two groups at 19 months, reflecting efficient rescue of IFN/LDAC failures with imatinib. Imatinib should now be considered the standard therapy for newly diagnosed patients with CML.

References

Mar 1, 1988·Journal of General Internal Medicine·B K MacDougall, B H Weinerman
Jan 1, 1968·Acta Haematologica·B Pedersen
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Feb 28, 2002·Blood·Michele BaccaraniUNKNOWN Italian Cooperative Study Group on Myeloid Leukemia
Mar 1, 2002·The New England Journal of Medicine·Hagop KantarjianUNKNOWN International STI571 CML Study Group
Mar 7, 2002·Lancet·A GratwohlA Urbano-Ispizua
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth A HahnUNKNOWN IRIS Investigators
Oct 10, 2003·The New England Journal of Medicine·Tim P HughesUNKNOWN International Randomised Study of Interferon versus STI571 (IRIS) Study Group

❮ Previous
Next ❯

Citations

Jan 1, 2011·Revista brasileira de hematologia e hemoterapia·Monika ConchonJosé Wilson Ramos Braga Junior
Sep 25, 2014·American Journal of Hematology·Juan M Alonso-DominguezGareth Gerrard
Mar 9, 2012·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Prathima ProdduturiMojtaba Akhtari
Sep 3, 2008·Bone Marrow Transplantation·L MagroI Yakoub-Agha
Nov 28, 2008·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Fernanda Gonçalves BassoCármino Antônio de Souza
Nov 24, 2005·Hematology·Michael W N Deininger
Jun 21, 2007·The Journal of Clinical Endocrinology and Metabolism·J W B de GrootE E Voest

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
T P HughesInternational Randomised Study of Interferon versus STI571 (IRIS) Study Group
The New England Journal of Medicine
Christophe Mauge, Sean Lilienfeld
© 2022 Meta ULC. All rights reserved